Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 April 2022
Seminar on Open Science

Publishing academic content behind a paywall not only limits access to scholarly work, but also prevents research output from being visible and making maximum impact. Researchers are paying to publish their research output, and libraries are paying to access it in what is known as double-dipping by publishers, leading to what we term ‘serial crisis’. Research institutions pay twice and still do not see their research widely available to be read.

By signing the Berlin Declaration on Open Access in 2012, the University of the Free State (UFS) committed itself to supporting open access to its research outputs. National initiatives by research institutions and the government make research outputs freely available via national site licensing. The UFS supports this initiative via the South African National Library and Information Consortium (SANLiC) as an interim transformative agreement with publishers, allowing research outputs to be open access, without the additional publication charges.

What do we do about publishers who are unwilling to transform? Do we still pay their massive subscription and publication fees? What do we need to do to ensure that all UFS research outputs are accessible to all?

Topic: Should the UFS continue to subscribe to academic journals that are behind a paywall?
Thursday 12 May 2022
12:00-13:30

Microsoft Teams
RSVP: Elma Viljoen, viljoene@ufs.ac.za (link will be provided)

Join the following top experts for what promises to be an insightful discussion:

  • Colleen Campbell
    Coordinator: Open Access 2020 Initiative
    Max Planck Digital Library, Munich, Germany
  • Ellen Tise
    Senior Director: Library and Information Services, Stellenbosch University

  • Glenn Truran
    Director: South African National Library and Information Consortium (SANLiC)

The welcoming and introduction to the webinar will be conducted by Prof Corli Witthuhn, Vice-Rector: Research.  

Bios of speakers

Colleen Campbell leads external engagement in the open access transition at the Max Planck Digital Library (MPDL) in Munich, Germany. There, she coordinates the Open Access 2020 Initiative, a global alliance of research organisations and their libraries that are driving the transition of today’s scholarly journals to open-access publishing models, and the ESAC Initiative, an international community of practice dedicated to optimising open-access workflows and processes. She is a member of the LIBER Open Access Working Group, serves on the Managing Board of EIFL, a not-for-profit organisation that works with libraries to enable access to knowledge in developing and transition economy countries in Africa, Asia-Pacific, Europe, and Latin America, and contributes to the advisory groups of a number of other scholarly communication initiatives.

Ellen Tise has been the Senior Director of Library and Information Services at Stellenbosch University (SU) since January 2006. She previously held the positions of University Librarian at the University of the Western Cape (UWC) and Deputy University Librarian at the University of the Witwatersrand. She holds a BBibl Honours degree from the UWC and an MPhil in Science and Technology Studies from SU. Among other notable leadership roles, Ms Tise served as the first President of the Library and Information Association of South Africa (LIASA) from 1998 to 2002, and President of the International Federation of Library Associations and Institutions, known as IFLA, for the years 2009 through 2011. She also served as Chair of the Board of the National Library of South Africa (2012-2015), and on the OCLC Board of Trustees (2014-2018). She has just started a second two-year term as Chair of the Freedom of Access to Information and Freedom of Expression Advisory Committee of IFLA. She is the recipient of several awards for distinguished leadership and outstanding contributions to librarianship, including honorary membership of LIASA and an honorary IFLA fellowship. She has published various articles in professional journals and is a regular speaker at national and international conferences, seminars, symposia, etc.

Glenn Truran has been the Director of the South African National Library and Information Consortium (SANLiC) since 2014 and works from home in Cape Town. After graduating from the University of the Witwatersrand (Wits) with a BA and HDipEd (PG), he worked briefly as an educator in South Africa and England. Subsequently, he completed a diploma in Public Policy and Development Administration at Wits and received his MBA from the University of Cape Town in 2003. Before joining SANLiC, he worked in several educational and poverty alleviation non-profit organisations in Gauteng and Cape Town. He has been actively involved in SANLiC’s Open Access Transformational Agreements task team.

Charlie Molepo has been the Deputy Director at the UFS Sasol Library responsible for Research and Scholarly Communications since 2015. He represents the non-academic staff on the University Council and serves on its Finance and Human Resources Committees. Before joining the UFS, he worked at Vista University, the University of Natal, the University of Johannesburg, the University of KwaZulu-Natal Libraries, and Dawson Books UK (Betrams) as the International Account Director for Africa. He serves as President-Elect (2022-2023) in the Library and Information Association of South Africa (LIASA).

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept